Identifying risk factors for COPD and adult-onset asthma: an umbrella review.

"Provenance: Submitted article, peer reviewed.: Conflict of interest: A.H. Maitland-Van der Zee is the PI of P4O2 (Precision Medicine for more Oxygen) public–private partnership sponsored by Health Holland involving many private partners who contribute in cash and/or in kind. Partners in the Precision Medicine for more Oxygen (P4O2) consortium are the Amsterdam UMC, Leiden University Medical Center, Maastricht UMC+, Maastricht University, UMC Groningen, UMC Utrecht, Utrecht University, TNO, Aparito, Boehringer Ingelheim, Breathomix, Clear, Danone Nutricia Research, Fluidda, MonitAir, Ncardia, Ortec Logiqcare, Philips, Proefdiervrij, Quantib-U, RespiQ, Roche, Smartfish, SODAQ, Thirona, TopMD, Lung Alliance Netherlands (LAN) and the Lung Foundation Netherlands (Longfonds). The consortium is additionally funded by the PPP Allowance made available by Health Holland, Top Sector Life Sciences & Health (LSHM20104; LSHM20068), to stimulate public-private partnerships and by Novartis. A.H. Maitland-Van der Zee has received grants from Boehringer Ingelheim, Vertex Innovation Award, Dutch Lung Foundation, Stichting Asthma Bestrijding, and Innovative Medicine Initiative (IMI). A.H. Maitland-Van der Zee has received consulting fees from AstraZeneca and Boehringer Ingelheim. A.H. Maitland-Van der Zee has received GSK honarium for a lecture. A.H. Maitland-Van der Zee is the chair of DSMB SOS BPD study and advisory board member of the CHAMP study. A.H. Maitland-Van der Zee is the president of the federation of innovative drug research in the Netherlands (FIGON) and president of the European Association of systems medicine (EASYM). The remaining authors have no conflicts to declare."

"Conflict of interest: A.H. Maitland-Van der Zee is the PI of P4O2 (Precision Medicine for more Oxygen) public–private partnership sponsored by Health Holland involving many private partners who contribute in cash and/or in kind. Partners in the Precision Medicine for more Oxygen (P4O2) consortium are the Amsterdam UMC, Leiden University Medical Center, Maastricht UMC+, Maastricht University, UMC Groningen, UMC Utrecht, Utrecht University, TNO, Aparito, Boehringer Ingelheim, Breathomix, Clear, Danone Nutricia Research, Fluidda, MonitAir, Ncardia, Ortec Logiqcare, Philips, Proefdiervrij, Quantib-U, RespiQ, Roche, Smartfish, SODAQ, Thirona, TopMD, Lung Alliance Netherlands (LAN) and the Lung Foundation Netherlands (Longfonds). The consortium is additionally funded by the PPP Allowance made available by Health Holland, Top Sector Life Sciences & Health (LSHM20104; LSHM20068), to stimulate public-private partnerships and by Novartis. A.H. Maitland-Van der Zee has received grants from Boehringer Ingelheim, Vertex Innovation Award, Dutch Lung Foundation, Stichting Asthma Bestrijding, and Innovative Medicine Initiative (IMI). A.H. Maitland-Van der Zee has received consulting fees from AstraZeneca and Boehringer Ingelheim. A.H. Maitland-Van der Zee has received GSK honarium for a lecture. A.H. Maitland-Van der Zee is the chair of DSMB SOS BPD study and advisory board member of the CHAMP study. A.H. Maitland-Van der Zee is the president of the federation of innovative drug research in the Netherlands (FIGON) and president of the European Association of systems medicine (EASYM). The remaining authors have no conflicts to declare. Support statement: Partners in the Precision Medicine for more Oxygen (P4O2) consortium are the Amsterdam UMC, Leiden University Medical Center, Maastricht UMC+, Maastricht University, UMC Groningen, UMC Utrecht, Utrecht University, TNO, Aparito, Boehringer Ingelheim, Breathomix, Clear, Danone Nutricia Research, Fluidda, MonitAir, Ncardia, Ortec Logiqcare, Philips, Proefdiervrij, Quantib-U, RespiQ, Roche, Smartfish, SODAQ, Thirona, TopMD, Lung Alliance Netherlands (LAN) and the Lung Foundation Netherlands (Longfonds). The consortium is additionally funded by the PPP Allowance made available by Health Holland, Top Sector Life Sciences & Health (LSHM20104; LSHM20068), to stimulate public-private partnerships and by Novartis. Funding information for this article has been deposited with the Crossref Funder Registry."

"We conducted an umbrella review, a systematic collection and assessment of multiple systematic reviews and meta-analyses []. The review was conducted according to the study protocol, registered in the International Prospective Register of Systematic Reviews (PROSPERO-CRD42021284614) and according to PRISMA guidelines. The full PRISMA checklist can be found in the supplemental material."